[The efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of 9 cases of relapsed/refractory diffuse large B-cell lymphoma after failing CAR-T cell therapy].
{"title":"[The efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of 9 cases of relapsed/refractory diffuse large B-cell lymphoma after failing CAR-T cell therapy].","authors":"H Zhang, X Y He, X Xiao, H R Lyu, M F Zhao","doi":"10.3760/cma.j.cn121090-20251219-00604","DOIUrl":null,"url":null,"abstract":"<p><p>To evaluate the efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) after failure of chimeric antigen receptor T (CAR-T) cell therapy. Nine patients with R/R DLBCL who failed CAR-T therapy and received glofitamab combined with polatuzumab vedotin treatment at the Hematology Department of Tianjin First Central Hospital from March 2024 to April 2025 were selected for retrospective analysis of their clinical data. The overall response rate was 77.8%, and the complete response rate was 55.6% following six cycles of treatment. The median follow-up period was 12 (5-18) months. The 1-year progression-free survival rate and overall survival rate were 71.1% (95% <i>CI</i>: 56.3%-86.1%) and 76.2% (95% <i>CI</i>: 64.0%-94.2%), respectively. All 9 patients experienced cytokine release syndrome, with 7 cases at grade 1-2 and 2 cases at grade 3. One patient had grade 1 immune effector cell-associated neurotoxicity syndrome. Glofitamab combined with polatuzumab vedotin shows preliminary efficacy and a manageable safety in patients with R/R DLBCL after CAR-T cell therapy failure.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"704-707"},"PeriodicalIF":0.0000,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575533/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/cma.j.cn121090-20251219-00604","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
To evaluate the efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) after failure of chimeric antigen receptor T (CAR-T) cell therapy. Nine patients with R/R DLBCL who failed CAR-T therapy and received glofitamab combined with polatuzumab vedotin treatment at the Hematology Department of Tianjin First Central Hospital from March 2024 to April 2025 were selected for retrospective analysis of their clinical data. The overall response rate was 77.8%, and the complete response rate was 55.6% following six cycles of treatment. The median follow-up period was 12 (5-18) months. The 1-year progression-free survival rate and overall survival rate were 71.1% (95% CI: 56.3%-86.1%) and 76.2% (95% CI: 64.0%-94.2%), respectively. All 9 patients experienced cytokine release syndrome, with 7 cases at grade 1-2 and 2 cases at grade 3. One patient had grade 1 immune effector cell-associated neurotoxicity syndrome. Glofitamab combined with polatuzumab vedotin shows preliminary efficacy and a manageable safety in patients with R/R DLBCL after CAR-T cell therapy failure.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
